The novel early response gene p22/PRG1 is linked to cell cycle entry and the induction of proliferation in various cell types although its exact function is still unknown. The p22/PRG1 promoter region contains a 20 bp sequence matching the consensus binding motif for the tumor suppressor protein p53. Gel shift assays demonstrated that p53 speci®cally binds to an oligonucleotide derived from the p53 binding site of the p22/PRG1 promoter. Chloramphenicol acetyltransferase (CAT) reporter gene assays con®rmed that this site confers p53-dependent transcriptional activity to the p22/PRG1 promoter. In Hela cells, p22/PRG1 promoter constructs induced CAT expression only when cotransfected with an expression plasmid for wild-type, but not for mutant p53. Similarly, CAT expression was inducible at the permissive (318C) but not at the non-permissive temperature (398C) in the rat embryo ®broblast-derived cell line clone-6 that expresses a temperature-sensitive mutant p53. Conversion of this mutant p53 to a functional p53 at the permissive temperature was accompanied by a signi®cant increase of endogenous p22/PRG1 mRNA level in this cell line. g-irradiation of rat splenocytes or doxorubicin-treatment of Hela cells increased p53 levels followed by transcriptional activation of p22/PRG1 and p21/Waf1 in parallel. Our data demonstrate that p22/PRG1 transcription is induced by p53 during p53-dependent cell cycle arrest and apoptosis. Therefore, p22/PRG1 represents a novel target for transcriptional activation by p53.
Introduction
Using the mRNA dierential display technique, we have identi®ed and cloned a novel early response gene (SchaÈ fer et al., 1996a) in rat AR4-2J pancreatic carcinoma cells growth-stimulated (Buscail et al., 1992; SchaÈ fer et al., 1996b) by administration of the regulatory peptide pituitary adenylate cyclase activating peptide, PACAP (Miyata et al., 1989) . This gene designated p22/PRG1 (PACAP response gene 1) encodes a 160 amino acid protein of 22 kDa and is closely related to gly96 (Charles et al., 1993) , a murine growth factor-inducible early response gene with an as yet unknown function. p22/PRG1 and gly96 are expressed in various tissues and act as growthassociated early response genes (Charles et al., 1993; SchaÈ fer et al., 1996a) . Transcription of p22/PRG1 is rapidly and transiently induced in various proliferating cells stimulated by growth stimuli like PACAP, epidermal growth factor, hepatocyte growth factor or serum. Furthermore, p22/PRG1 seems to be involved in the development of feedback-induced hyperplasia of the rat pancreas (SchaÈ fer et al., 1996a) . More recently, a human early response gene, IEX1, has been described that is transiently induced in response to g-irradiation and exhibits high structural similarity with p22/PRG1 and gly96 (Kondratyev et al., 1996) . p22/PRG1 and its putative human homolog IEX1 most likely represent early response genes that are regulated at the transcriptional level in response to various stimuli, i.e. induction of growth, cellular stress, or loss of cellular integrity (H SchaÈ fer, P Lettau, A Trauzold, M Banasch and WE Schmidt, manuscript in preparation). However, the role of p22/PRG1 and its homologs in the context of cellular proliferation, repair or adaptation remains to be de®ned. In order to characterize the potential function of this gene, we examined the promoter region of p22/PRG1 and identi®ed various putative binding sites for transcription factors which might be involved in the regulation of p22/PRG1 expression at dierent stages of growth control and other cellular functions.
In the present work, we identi®ed a DNA transactivation site for the tumor suppressor p53 located in the promoter of rat p22/PRG1. p53 is a crucial regulator of the cell cycle, an important mediator of apoptosis in DNA-damaged cells and has been regarded as being responsible for the maintenance of genomic stability (Baker et al., 1990; Mercer et al., 1990) . The development of a wide range of malignant tumors is characterized by the mutational inactivation of p53 (Hollstein et al., 1991) . The p53 binding site of the p22/PRG1 promoter is highly similar to the distal p53 binding-site located in the promoter of p21/Waf1 (El-Deiry et al., 1995) . This well-characterized p53 target gene is directly involved in G 1 cell cycle arrest (El-Deiry et al., 1994) and represents a key mediator of p53-dependent growth control. We demonstrate here that the p53 binding-site in the p22/PRG1 promoter is functional and mediates transcriptional activation of p22/PRG1 in a fashion similar to p21/Waf1.
Results
Identi®cation of a putative binding-site for wild-type p53 residing within the p22/PRG1 promoter Based on homology alignment, a putative binding site for the tumor suppressor protein p53 was identi®ed at positions 7280 to 7261 (Figure 1a ) of the p22/PRG1 promoter (SchaÈ fer et al., 1996a) . This palindromic 20 bp sequence, CCACATGTCCCGACATGTGC, strongly matches the tandem 10 bp motif RRRC(A/ T)(A/T)GYYY, described as a consensus p53 recognition-sequence Zambetti et al., 1992) and comparison with p53 binding-sites of established p53 target genes (Figure 1b) revealed the highest similarity with the distal p53 binding site of the p21/Waf1 promoter (El-Deiry et al., 1995) . Based upon homology to the p53 consensus region, the binding site identi®ed in the p22/PRG1 promoter ®ts into the structural requirements shared by at least one of the other p53 target genes. The tandem p53 binding site is directly preceded by an additional decamer ( Figure 1a ) with similarity to the p53 binding motif that probably enhances the interaction of p53 with the p22/PRG1 promoter (Bourdon et al., 1997) . In addition, the p53 binding-site is followed by an A-rich region located 80 bp downstream consisting of four repeats of 5 ± 8 adenines. A similar structural feature has been identi®ed in the promoter of bax (FriedlaÈ nder et al., 1996) , an important mediator of p53 induced apoptosis (Miyashita et al., 1994) .
Analysis of the binding activity of the p22/PRG1 promoter-derived p53 binding-site
To demonstrate binding of wild-type p53 to its putative binding-site of the p22/PRG1 promoter, gel shift assays were performed with baculovirus recombinant p53 and a 24 bp oligonucleotide derived from positions 7260 to 7283 of the p22/PRG1 promoter as probe. As shown in Figure 2a , two strongly radiolabelled protein/ DNA complexes became visible (Lane 1) that presumably consist of the p53 tetramer and a higher aggregate of p53 (Stenger et al., 1992) . Addition of a 50-fold excess of unlabelled oligonucleotide strongly reduced labelling of the protein/DNA complex ( Figure  2a , lane 2). In contrast, no displacement occurred in the presence of a 100-fold excess of a control oligonucleotide like AP1 (Figure 2a, lane 3) . Addition of a monoclonal antibody recognizing the C-terminus of p53 produced a supershifted band (Figure 2a , lane 4) indicating that the labelled protein/DNA complex indeed contains p53. In contrast, a control antibody induced no supershift thus excluding unspeci®c binding of the anti-p53 antibody (data not shown). Furthermore, coincubation of the labelled p53 binding-site with a nuclear extract from human SV-80 ®broblasts (Gish and Botchan, 1987) exhibiting high level expression of wild-type p53 produced a strongly labelled protein/DNA complex ( Figure 2b) . A similar complex was detected with the labelled p53 binding site of the p21/Waf1 promoter ( Figure 2b ). Labelling of this complex was dose-dependently diminished in the presence of the unlabelled homologous oligonucleotide at a 100-and 50-fold molar excess or by the unlabelled p53 binding-site of the p21/WAF-1 promoter. By contrast, no label displacement was observed with a p53-unrelated sequence-like Oct-1.
Transcriptional activation of the p22/PRG1 promoter by transient cotransfection with pCMV-p53 in Hela cells Hela cells were transiently cotransfected with CAT vectors containing segments of the p22/PRG1 promoter and a CMV promoter-driven wild-type p53 expression plasmid (StuÈ rzbecher et al., 1987) . Two of the p22/PRG1 promoter fragments, pPRG(7589) and pPRG(7356), contain the p53 binding site, whereas the promoter fragments pPRG(7186) and pPRG (7589D 7262/7281 ) lack this site. As shown in Figure 3a , cells cotransfected with pCMV-p53(wt) and pPRG(7589) or pPRG(7356) exhibited a 3 ± 4-fold higher CAT expression compared to cells cotransfected with equal amounts of pPRG(7589) or pPRG(7356) and the control plasmid pCMV-lacZ. In contrast, no increase but rather a slight decrease of ). To test the speci®city of the inducing eect of wild-type p53 on p22/PRG1 promoter-driven CAT transcription, Hela cells were cotransfected with a CMV promoter-driven expression plasmid of mutant, pCMV-C5p53. This mutant p53 contains two mutations at amino acid 168 and 234 (Eliyahu et al., 1988) , therefore lacking its speci®c DNA-binding and transactivating capacity. Compared to the controls, expression of the CAT reporter gene was not elevated in cells cotransfected with pCMVC5p53 and either of the promoter-CAT plasmids. Instead, CAT expression was partially reduced (Figure 3a ).
Transcriptional activation of the p22/PRG1 promoter in clone-6 cells expressing temperature-sensitive mutant p53
A speci®c, p53-dependent activation of the p22/PRG1 promoter was also demonstrated in the rat embryonic ®broblast-derived cell line clone-6 stably transfected with a temperature-sensitive dominant negative mutant ) or pPRG(7186) were transiently cotransfected with 1 mg pCMV-lacZ in clone-6 cells. After overnight culture at 398C, cells were further incubated at 398C or at 318C for 24 h. CAT expression was determined as described above; (mean+s.d., n=5) of murine p53, p53(Val135) (Michalovitz et al., 1990) . As shown in Figure 3b , clone-6 cells transfected with pPRG(7589) exhibited a 2 ± 3-fold higher CAT expression upon 24 h incubation at the permissive temperature (318C) compared to cells incubated at the non-permissive temperature (398C). Since in control transfectants the expression of b-galactosidase was slightly reduced at the permissive temperature the positive eect on CAT expression under these conditions is not due to distinct transfectants/total cell ratios. No signi®cant dierence of CAT expression at both temperatures was observed in clone-6 cells transfected with pPRG(7589D
7262/7281
) and pPRG(7186), suggesting that the increase of CAT expression at the lower temperature is directed by the resident p53 binding-site of the p22/PRG1 promoter.
Wild-type p53 increases endogenous p22/PRG1 expression in clone-6 cells Clone-6 cells also provided a suitable system to analyse the p53-dependent expression of the endogenous p22/ PRG1 gene. Clone-6 cells grown at 398C were shifted to 318C for various time periods, and mRNA levels of p22/PRG1 and p21/Waf1 were analysed by RT ± PCR. The status of p53 was examined by immunoblotting of cell extracts or by immuno¯uorescence microscopy using a monoclonal antibody against wild-type and mutant p53. As shown in Figure 4a , the level of p53(mut) protein that was high in cells cultured at 398C began to decrease after 3 ± 6 h in clone-6 cells cultured at 318C. After 12 ± 24 h, considerably reduced steady state levels of p53 protein were detected. This decline of p53 protein levels is indicative for the shift from inactive p53 (at 398C) to active p53 (at 318C) due to a conformational change of the mutated p53 protein (Ginsberg et al., 1991; Michalovitz et al., 1990; Olson and Levine, 1994; Zerrahn et al., 1992) . As shown by immuno¯uorescence staining of clone-6 cells ( Figure  4b ), p53 began also to translocalize from the cytoplasm (left panel) into the nucleus after 6 h (right panel). This nuclear localization was similarly observed after 12 h and 24 h (data not shown). Concomitant with the decrease of p53 protein levels and its nuclear translocation, transcription of endogenous p22/PRG1 increased in clone-6 cells. As shown by RT ± PCR (Figure 5a,b) , the mRNA level of p22/PRG1 began to rise 6 h upon the temperature shift to 318C and reached a maximum after 24 h. Compared to p22/ PRG1, elevation of p21/Waf1 mRNA levels occurred earlier at the permissive temperature (after 3 h) and reached a steady state maximum after 12 h.
In contrast to p22/PRG1 and p21/Waf1, b-actin mRNA levels did not change signi®cantly (Figure 5a ), strongly suggesting that the increase of the mRNA levels of both former genes correlates with the rise of p53-dependent transcriptional activity. In addition, no comparable p22/PRG1-and p21/Waf1-expression was observed in control cell lines at 318C (not shown), indicating that the increased expression at 318C in clone-6 cells depends on the gain of wild-type like p53 activity.
Parallel increase of p22/PRG1 and p21/Waf1 mRNA levels during p53-dependent apoptosis
In order to investigate the p53 related induction of p22/PRG1 under physiological conditions, rat mononuclear splenocytes, mainly CD3 + T-cells (CD4 + and CD8 + ), were exposed to g-irradiation. This treatment results in DNA-damage and induces p53 dependent cell cycle arrest (Aloni-Grinstein et al., 1995) and apoptosis (Seki et al., 1994) within 24 h (data not shown). Semiquantitative RT ± PCR revealed that upon girradiation p22/PRG1 mRNA levels signi®cantly increased in rat splenocytes within 4 ± 8 h and reached a maximum after 16 h (Figure 6a) . In direct comparison, mRNA levels of p21/Waf1 exhibited an almost identical time course of induction in response to irradiation (Figure 6a ). To investigate whether the inducing eect of g-irradiation on p22/PRG1 transcription is related to p53-activation, expression of p22/ PRG1 was analysed by semiquantitative RT ± PCR in g-irradiated Saos-2 cells which are de®cient of p53 and resistant to apoptosis (Chen et al., 1990) . As shown in Figure 6b , p22/PRG1 mRNA levels were only moderately increased within 2 h, an early eect that is presumably due to NFkB activation upon irradiation (Kondratyev et al., 1996) . Then, the mRNA content of p22/PRG1 continuously declined between 4 ± 24 h after irradiation. In comparison, high basal p21/Waf1 mRNA levels did not change signi®cantly within the ®rst 4 h but similarly declined thereafter (Figure 6b) .
Transcription of p22/PRG1 and p21/Waf1 was similarly induced in doxorubicin treated Hela cells which revealed a substantial increase of p53 protein levels after 12 ± 24 h. As shown by RT ± PCR ( Figure  7a ), p22/PRG1 and p21/Waf1 mRNA levels rose in parallel within 12 ± 24 h and reached a 7 ± 10-fold maximal increase after 48 h. A signi®cant portion (430%) of Hela cells underwent apoptosis 48 h upon drug administration as indicated by the presence of nuclear fragments and apoptotic bodies (Figure 7b ).
Discussion
We recently identi®ed p22/PRG1 as a putative rat early response gene (SchaÈ fer et al., 1996a) but the precise cellular function of p22/PRG1 and its murine (gly96) or human (IEX1) homologue (Charles et al., 1993; Kondratyev et al., 1996) as growth-associated early response genes is still unknown. Examination of the p22/PRG1 promoter revealed that it contains several potential binding sites for transcription factors which are linked to distinct signalling pathways and mediate growth stimulatory, growth-inhibitory or differentiation signals.
As a remarkable property of the p22/PRG1 promoter, we have identi®ed a DNA binding site for the tumor suppressor p53 which is highly similar to the p53 transactivation site in the p21/Waf1 promoter (El- Deiry et al., 1995) and ful®ls all criteria required for a functional p53 binding site. Gel shift and supershift assays demonstrate that recombinant and nuclear wildtype p53 bind to this regulatory sequence. This site also confers transcriptional activity to the p22/PRG1 promoter in a p53-dependent fashion, as shown by cotransfection of wild-type p53 and p22/PRG1-CAT reporter gene constructs containing the resident p53 binding-site. Furthermore, expression of p22/PRG1 is induced in clone-6 cells in a wild-type p53-dependent fashion. Endogenous mRNA levels of p22/PRG1 increased in this cell line at the permissive temperature of 318C ( Figure 5 ) that promotes mutant p53 to adopt a conformation equivalent to wild-type p53, to overcome its nuclear exclusion at 398C (Figure 4b ) and to transcriptionally induce its target genes, i.e. p21/ Waf1 (Michalovitz et al., 1990; Knippschild et al., 1996) . Since our experiments demonstrated that in clone-6 cells the translocation of p53 into the nucleus is followed by increased transcription of p21/Waf1 ( Figure 5 ), it can be concluded that the elevation of p22/PRG1 mRNA level at 318C in these cells similarly depends on active p53, thus qualifying p22/PRG1 as a p53 responsive gene in vivo. The slightly dierent time kinetics of p22/PRG1 and p21/Waf1 expression could be attributed to time-dependent changes in the transactivating potential of p53 on these two target genes upon the shift to the permissive temperature. Such a time-dependent modulation of target gene selectivity of temperature sensitive mutant p53 has been demonstrated for p21/Waf1 and mdm2 (Martinez et al., 1997) . The p53 binding-site of the p22/PRG1 promoter is anked by a slightly more degenerated decameric p53 binding motif that might contribute a second tandem decamer enhancing p53 transactivation (Bourdon et al., 1997) and by an A-rich region similarly present in the bax promoter (FriedlaÈ nder et al., 1996) where it has been proposed to be a modulatory element for p53 binding. The presence of these two additional elements which putatively enhance transcriptional activation by p53 (Bourdon et al., 1997; FriedlaÈ nder et al., 1996) strongly support the physiological relevance of the p53 binding site, despite its degeneration in four positions compared to the consensus motif. Trans-activation via this site might be modulated depending on the cellular context and restricted to particular p53 modi®cations that include phosphorylations (Hecker et al., 1996; Martinez et al., 1997) and proteolytic cleavage in response to DNA damage (Molinari et al., 1996) both believed to direct the mode of p53 actions.
Among the multiple actions of p53 as regulator of cell growth and cell viability, its function as site-speci®c transcription factor is as yet best understood. Various p53 target genes are directly involved in cell cycle arrest, i.e. p21/Waf1 (El-Deiry et al., 1994) , in apoptosis, i.e. bax (Miyashita and Reed, 1995) or in DNA-repair, i.e. PCNA (Morris et al, 1996; Shivakumar et al., 1995) and GADD45 (Kastan et al., 1992) . Via these target genes p53 organizes an adequate cellular response to DNA damage induced by irradiation or genotoxic agents. This response may result in DNA repair or the induction of apoptosis, hereby avoiding propagation of potentially mutated cells. An involvement of p22/PRG1 in p53-dependent apoptosis is indicated by the ®nding that its expression is increased in g-irradiated rat splenocytes. Transcription of p22/PRG1 and p21/Waf1 is strongly induced in parallel (Figure 6a ) preceded by elevated p53 protein levels. This may indicate that the transcriptional induction of p22/PRG1 in these g-irradiated cells is linked to cell cycle arrest and/or subsequent activation of an apoptotic pathway (Clarke et al., 1993; Lowe et al., 1993) . Both phenomena involve transactivation by p53 in response to DNA damage (Aloni-Grinstein et al., 1995; Seki et al., 1994; Bae et al., 1995) . In support of this conclusion, very similar results were obtained in another model of p53-dependent apoptosis (Ling et al., 1993; Tishler et al., 1993) . Hela cells treated with the DNA damaging drug doxorubicin strongly express p53 followed by a parallel increase of p22/PRG1 and p21/ WAF1 mRNA levels and the onset of apoptosis in a high portion of cells. In contrast, g-irradiation of p53 de®cient Saos-2 cells did neither induce p22/PRG1 and p21/Waf1 expression (Figure 6b ) nor apoptosis. This observation strongly supports the view that the DNAdamage induced expression of these two genes in both apoptotic models is related to the activation of p53. Our ®ndings that in both experimental systems transcription of p22/PRG1 was induced in parallel with p21/Waf1 strongly suggest that p22/PRG1 may contribute to p53-dependent growth control in DNAdamaged cells. As an early event upon p53-mediated transactivation, p21/Waf1 imposes a G1 arrest on these cells hereby providing the opportunity for DNA repair and enabling subsequent cell recovery instead of apoptosis. A prolonged expression of p21/Waf1 keeps the cells in growth arrest and may thereby protect them from apoptosis (Polyak et al., 1996) . Since expression of p22/PRG1 has also been observed during G0/G1 transition (Charles et al., 1993; SchaÈ fer et al., 1996) , it is tempting to speculate that co-expression of p21/Waf1 and p22/PRG1 may provide a con¯icting growth signal that has been described as a major cause of apoptosis, i.e. by c-myc (Evan et al., 1992; Saito and Ogawa, 1995) . A putative recruitment of p22/PRG1 by p53 in this way would be compatible with a dual role of p53: it is required for permanent growth arrest and/or apoptosis in cells that failed to recover from DNA-damage, but also favours growth of cells that overcome DNA aberrations. This growth promoting function of p53 might involve those target genes like TGFa (Shin et al., 1995) or mdm2 (Wu et al., 1993; Xiao et al., 1995) .
Materials and methods

Materials
Clone-6 cells were kindly donated by Dr Moshe Oren, Weizmann Institute, Rehovot, Israel and SV80 cells were provided by Dr Holger Kaltho, Laboratory of Molecular Oncology, Department of General Surgery, University of Kiel, Germany. Oligonucleotides were from Biometra (GoÈ ttingen, Germany). Reagents and enzymes for reverse transcription and PCR were from GIBCO/BRL.
Cell culture
HeLa cells were cultured in DMEM plus 10% fetal calf serum (FCS) at 378C (5% CO 2 , 85% humidity). Clone-6 cells were kept in culture using DMEM plus 5% FCS at 398C (non permissive temperature) or at 318C (permissive temperature), 5% CO 2 and 85% humidity. The human osteosarcoma cell line Saos-2 (DSMZ, Braunschweig, FRG) was cultured in McCOY 5A medium (GIBCO-BRL) plus 10% FCS at 378C (5% CO 2 , 85% humidity).
Gel shift assay for p53
Nuclear extracts from SV-80 cells cultured in RPMI 40 medium supplemented with 10% FCS were prepared as described (Schreiber et al., 1989) 15 mg of nuclear protein or 1 ml of baculovirus recombinant wild-type p53 (0.1 mg/ ml) were incubated for 30 min at room-temperature with 1 ml of a g-32 P-labelled oligonucleotide containing the p53 binding site derived from the p22/PRG1 promoter (TACCACATGTCCCGACATGTGCTT) and 18 ml of gel shift incubation buer (GelShift assay kit, Stratagene). For supershift assays, a monoclonal anti p53 antibody (Ab1, Calbiochem) was subsequently added for 1 h on ice. As positive control, an oligonucleotide was used (CAGGAA-CATGTCCCAACATGTTGAG) containing the distal p53 binding site of the human p21/Waf1 promoter.
Generation of chloramphenicol acetyl transferase (CAT) reporter gene constructs containing fragments of the p22/PRG1 promoter Using composite SalI/XbaI PCR-primers, various fragments of the p22/PRG1 promoter (pos 71 to 7589, 71 to 356, 71 to 7589, D 7262 to 7281 and 71 to 7186) were generated by PCR and cloned into the CAT-basic vector (Promega). All constructs were checked by nucleotide sequencing.
Transient cotransfection and assay for CAT activity
HeLa cells or clone-6 cells were cultured in 6 cm culture dishes until 60 ± 80% con¯uency, followed by incubation with serum-free medium for 30 min. 2.5 mg of pCAT vectors containing the p22/PRG1 promoter fragments were incubated at room temperature in 600 ml serum-free medium plus 30 ml Lipofectamine 1 (GIBCO-BRL). For cotransfection of HeLa cells, 1 mg of CMV early enhancer promoter-driven expression plasmids for wild-type p53 (pCMV-p53) or mutant p53 (pCMV-c5p53) were added to the CAT plasmids plus 1 mg of pCMV-lacZ (Eurogentech), and for transfection of clone-6 cells, 1 mg of pCMV-lacZ was added to the CAT plasmids. Plasmid mixtures were brought to 3 ml with serum-free medium and incubated with cells under standard culture conditions for 6 h. Then, HeLa cells were cultured in DMEM plus serum for 36 h; clone-6 cells were cultured at 398C for 18 h followed by culture at 398C or 318C for 24 h. Transfection ecacy was determined by b-galactosidase activity (b-gal assay, Boehringer) and CAT expression was determined in duplicate using a CAT-ELISA (Boehringer) and calculated as ng CAT protein/mU b-gal. The expression of wild-type p53 and mutant p53 was checked by immunoblotting and RT ± PCR. g-irradiation of rat splenocytes or Saos-2 cells and doxorubicin-treatment of HeLa cells Rat splenocytes were isolated and kept in short-term culture for 24 h, as described (Kruisbeek, 1993) . Splenocytes or Saos-2 cells were exposed to 8 Gy g-rays from a 137 Cs source (2 Gy/min). After various periods in culture, splenocytes or Saos-2 cells were harvested and prepared for immunoblotting and RT ± PCR. Subcon¯uent HeLa cells were incubated with 200 ng/ml doxorubicin for various periods and subsequently prepared for immunoblotting, RT ± PCR and immuno¯uorescence microscopy.
RT ± PCR analysis
Total RNA was isolated using the RNeasy kit (QIAGEN), heat-denatured (758C, 3 min) and (2 mg) submitted to RT ± PCR using the following primers: p22/PRG1 (SchaÈ fer et al., 1996b), ATGTGCCATTCGCGTAACCAC (sense), GAATGCCGCCGGGTGTTGCT (antisense); p21/Waf1, GGATGTCCGTCAGAACCCATGC (sense), TCCTCTT-GGAGAAGATCAGCCG (antisense). Cycling conditions (Thermal cycler 2400, Perkin Elmer) were: 958C, 2 min; 958C, 1 min/628C, 30 s/728C, 30 s, 3 cycles; 958C, 1 min/ 608C, 30 s/728C, 30 s, 3 cycles; 958C, 1 min/588C, 30 s/ 728C, 30 s, 12 or 15 cycles and 728C, 10 min. Amplimer set primers (Clontech) were used for the analysis of b-actin mRNA as control. PCR products were analysed by PAGE and ethidium bromide staining or quanti®ed by MiniQ p22/PRG1: a novel p53-responsive gene H Scha Èfer et al ionic exchange chromatography (SMART, Pharmacia) run with 10 mM Tris/HCl pH 7.4, 1 mM EDTA (TE-buer) and employing a linear NaCl gradient. OD 260 peak areas of p22/ PRG1 and p22/Waf1 were normalized to the OD 260 peak areas of b-actin; the corresponding ratios were used for semi-quantitative comparison. This semiquantitative method was evaluated in comparison to Northern hybridization, as described (SchaÈ fer et al., 1996a) .
Western blot analysis
Cells were lysed with 26SDS ± PAGE sample buer, heated (958C) for 5 min and submitted to 12.5% SDS ± PAGE. Separated proteins were electroblotted onto PVDF membranes (Amersham). Blots were exposed for 60 min at room temperature to an anti-mouse p53 monoclonal antibody (Ab1, Calbiochem) and developed using the Phototope immunoblot detection kit (NE Biolabs).
Immuno¯uorescence microscopy
Cells cultured on cover-slips were rinsed with PBS, ®xed with chilled methanol for 1 h at 7208C, washed three times with TBS for 10 min and exposed to 1 mg/ml of a monoclonal p53-antibody (Ab1, Calbiochem) for 45 min at 378C. After washing with TBS, cells were exposed to a FITC conjugated secondary anti-mouse antibody (Sigma) for 45 min at 378C in the dark and washed with TBS and distilled water. Then, cells were covered with Moviol solution. For nuclear staining, the Hoechst dye was used following the manufacturer's instructions.
Abbreviations PACAP, pituitary adenylate cyclase activating peptide; PRG1, PACAP response gene 1; DMEM, Dulbecco's modi®ed Eagles medium; FCS, fetal calf serum; CAT, chloramphenicol acetyl transferase; pCMV, plasmid containing the cytomegalovirus early enhancer promoter.
